22 October[removed]Christine Chapman Therapeutic Group Manager PHARMAC PO Box[removed]

First Page		Document Content
Date: 2013-11-07 15:04:11 Respiratory therapy Leukotriene antagonists Cyclopropanes Merck Montelukast Pharmaceutical Management Agency Exercise-induced asthma Asthma NZMA Pulmonology Medicine Healthcare in New Zealand		22 October[removed]Christine Chapman Therapeutic Group Manager PHARMAC PO Box[removed] Add to Reading List Source URL: www.nzma.org.nz Download Document from Source Website File Size: 172,85 KB Share Document on Facebook

	Leukotriene Modifiers (Accolate®, Singulair®, Zileuton®) What are They? DocID: 19NXJ - View Document
	Case study: Leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines Importance to NHS Around 5.4 million people in the UK are currently receiving treatment for asthma and the N DocID: 177Pa - View Document
	Table 2: Asthma Classification of Subjects and Medication Use Subject Lowest Daily Medication Required for Asthma Control Asthma Classification DocID: 15dYJ - View Document
	Int J Biol Med Res.2015;6(1):Int J Biol Med Res www.biomedscidirect.com Volume 3, Issue 1, Jan 2012 DocID: 1385d - View Document
	Dr Shabna Rajapaksa Consultant Paediatrician Ballarat Paediatric Clinic & Ballarat Health Services April 2013 DocID: 11wNn - View Document